M. Fleseriu Et Al. , "Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study," CLINICAL ENDOCRINOLOGY , vol.91, no.6, pp.776-785, 2019
Fleseriu, M. Et Al. 2019. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. CLINICAL ENDOCRINOLOGY , vol.91, no.6 , 776-785.
Fleseriu, M., Petersenn, S., Biller, B. M. K., Kadioglu, P., De Block, C., T'Sjoen, G., ... Vantyghem, M.(2019). Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. CLINICAL ENDOCRINOLOGY , vol.91, no.6, 776-785.
Fleseriu, Maria Et Al. "Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study," CLINICAL ENDOCRINOLOGY , vol.91, no.6, 776-785, 2019
Fleseriu, Maria Et Al. "Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study." CLINICAL ENDOCRINOLOGY , vol.91, no.6, pp.776-785, 2019
Fleseriu, M. Et Al. (2019) . "Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study." CLINICAL ENDOCRINOLOGY , vol.91, no.6, pp.776-785.
@article{article, author={Maria Fleseriu Et Al. }, title={Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study}, journal={CLINICAL ENDOCRINOLOGY}, year=2019, pages={776-785} }